Top

Published in:

01-04-2014 | Original Article

Age-related decline in dopamine transporter in human brain using PET with a new radioligand [¹⁸F]FE-PE2I

Authors: Yoshitoshi Shingai, Amane Tateno, Ryosuke Arakawa, Takeshi Sakayori, WooChan Kim, Hidenori Suzuki, Yoshiro Okubo

Published in: Annals of Nuclear Medicine | Issue 3/2014

Abstract

Objective

Dopamine transporter (DAT) density is considered as a marker of pre-synaptic function. Numerous neuroimaging studies have consistently demonstrated an age-related decrease in DAT density in normal human brain. However, the precise degree of the regional decline is not yet clear. The purpose of this study was to evaluate the effect of the normal aging process on DAT densities in human-specific brain regions including the substantia nigra and thalamus using positron emission tomography (PET) with [¹⁸F]FE-PE2I, a new PET radioligand with high affinity and selectivity for DAT.

Methods

Thirty-six healthy volunteers ranging in age from 22 to 80 years were scanned with PET employing [¹⁸F]FE-PE2I for measuring DAT densities. Region of interest (ROI)-based analysis was used, and ROIs were manually defined for the caudate, putamen, substantia nigra, thalamus, and cerebellar cortex. DAT binding was quantified using a simplified reference tissue model, and the cerebellum was used as reference region. Estimations of binding potential in the caudate, putamen, substantia nigra, and thalamus were individually regressed according to age using simple regression analysis. Estimates of DAT loss per decade were obtained using the values from the regression slopes.

Results

There were 7.6, 7.7, and 3.4 % per-decade declines in DAT in the caudate, putamen, and substantia nigra, respectively. By contrast, there was no age-related decline of DAT in the thalamus.

Conclusions

[¹⁸F]FE-PE2I allowed reliable quantification of DAT, not only in the caudate and putamen but also in the substantia nigra. From the results, we demonstrated the age-related decline in the caudate and putamen as reported in previous studies, and additionally for those in the substantia nigra for the first time.

Chou KL, Bohnen NI. Performance on an Alzheimer-selective odor identification test in patients with Parkinson’s disease and its relationship with cerebral dopamine transporter activity. Parkinsonism Relat Disord. 2009;15(9):640–3.PubMedCentralPubMedCrossRef

Kazumata K, Dhawan V, Chaly T, Antonini A, Margouleff C, Belakhlef A, et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med. 1998;39(9):1521–30.PubMed

Oh M, Kim JS, Kim JY, Shin K-H, Park SH, Kim HO, et al. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy. J Nucl Med. 2012;53(3):399–406.PubMedCrossRef

Ginovart N, Lundin A, Farde L, Halldin C, Bäckman L, Swahn CG, et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington’s disease. Brain. 1997;120(Pt 3):503–14.PubMedCrossRef

Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry. 2005;57(3):229–38.PubMedCrossRef

Nakamura K, Sekine Y, Ouchi Y, Tsujii M, Yoshikawa E, Futatsubashi M, et al. Brain serotonin and dopamine transporter bindings in adults with high-functioning autism. Arch Gen Psychiatry. 2010;67(1):59–68.PubMedCrossRef

Arakawa R, Ichimiya T, Ito H, Takano A, Okumura M, Takahashi H, et al. Increase in thalamic binding of [(11)C]PE2I in patients with schizophrenia: a positron emission tomography study of dopamine transporter. J Psychiatr Res. 2009;43(15):1219–23.PubMedCrossRef

Ishibashi K, Ishii K, Oda K, Kawasaki K, Mizusawa H, Ishiwata K. Regional analysis of age-related decline in dopamine transporters and dopamine D2-like receptors in human striatum. Synapse. 2009;63(4):282–90.PubMedCrossRef

Rinne JO, Sahlberg N, Ruottinen H, Någren K, Lehikoinen P. Striatal uptake of the dopamine reuptake ligand [11C]beta-CFT is reduced in Alzheimer’s disease assessed by positron emission tomography. Neurology. 1998;50(1):152–6.PubMedCrossRef

10.

Troiano AR, Schulzer M, de la Fuente-Fernandez R, Mak E, McKenzie J, Sossi V, et al. Dopamine transporter PET in normal aging: dopamine transporter decline and its possible role in preservation of motor function. Synapse. 2010;64(2):146–51.PubMedCrossRef

11.

Volkow ND, Fowler JS, Wang GJ, Logan J, Schlyer D, MacGregor R, et al. Decreased dopamine transporters with age in health human subjects. Ann Neurol. 1994;36(2):237–9.PubMedCrossRef

12.

Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley SJ, et al. Dopamine transporters decrease with age. J Nucl Med. 1996;37(4):554–9.PubMed

13.

Volkow ND, Wang GJ, Fowler JS, Ding YS, Gur RC, Gatley J, et al. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann Neurol. 1998;44(1):143–7.PubMedCrossRef

14.

Allard P, Marcusson JO. Age-correlated loss of dopamine uptake sites labeled with [3H]GBR-12935 in human putamen. Neurobiol Aging. 1989;10(6):661–4.PubMedCrossRef

15.

De Keyser J, Ebinger G, Vauquelin G. Age-related changes in the human nigrostriatal dopaminergic system. Ann Neurol. 1990;27(2):157–61.PubMedCrossRef

16.

Emborg ME, Ma SY, Mufson EJ, Levey AI, Taylor MD, Brown WD, et al. Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J Comp Neurol. 1998;401(2):253–65.PubMedCrossRef

17.

Hebert MA, Larson GA, Zahniser NR, Gerhardt GA. Age-related reductions in [3H]WIN 35,428 binding to the dopamine transporter in nigrostriatal and mesolimbic brain regions of the fischer 344 rat. J Pharmacol Exp Ther. 1999;288(3):1334–9.PubMed

18.

Zelnik N, Angel I, Paul SM, Kleinman JE. Decreased density of human striatal dopamine uptake sites with age. Eur J Pharmacol. 1986;126(1–2):175–6.PubMedCrossRef

19.

Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, Macgregor RR, et al. Mapping cocaine binding sites in human and baboon brain in vivo. Synapse. 1989;4(4):371–7.PubMedCrossRef

20.

Wong DF, Yung B, Dannals RF, Shaya EK, Ravert HT, Chen CA, et al. In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428. Synapse. 1993;15(2):130–42.PubMedCrossRef

21.

Farde L, Halldin C, Müller L, Suhara T, Karlsson P, Hall H. PET study of [11C]beta-CIT binding to monoamine transporters in the monkey and human brain. Synapse. 1994;16(2):93–103.PubMedCrossRef

22.

Ding YS, Fowler JS, Volkow ND, Gatley SJ, Logan J, Dewey SL, et al. Pharmacokinetics and in vivo specificity of [11C]dl-threo-methylphenidate for the presynaptic dopaminergic neuron. Synapse. 1994;18(2):152–60.PubMedCrossRef

23.

Laakso A, Bergman J, Haaparanta M, Vilkman H, Solin O, Hietala J. [18F]CFT [(18F)WIN 35,428], a radioligand to study the dopamine transporter with PET: characterization in human subjects. Synapse. 1998;28(3):244–50.PubMedCrossRef

24.

Davis MR, Votaw JR, Bremner JD, Byas-Smith MG, Faber TL, Voll RJ, et al. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT. J Nucl Med. 2003;44(6):855–61.PubMed

25.

Halldin C, Erixon-Lindroth N, Pauli S, Chou Y-H, Okubo Y, Karlsson P, et al. [(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Eur J Nucl Med Mol Imaging. 2003;30(9):1220–30.PubMedCrossRef

26.

Varrone A, Steiger C, Schou M, Takano A, Finnema SJ, Guilloteau D, et al. In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE-PE2I, a new dopamine transporter PET radioligand. Synapse. 2009;63(10):871–80.PubMedCrossRef

27.

Ito H, Sudo Y, Suhara T, Okubo Y, Halldin C, Farde L. Error analysis for quantification of [(11)C]FLB 457 binding to extrastriatal D(2) dopamine receptors in the human brain. Neuroimage. 2001;13(3):531–9.PubMedCrossRef

28.

Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4(3 Pt 1):153–8.PubMedCrossRef

29.

Sasaki T, Ito H, Kimura Y, Arakawa R, Takano H, Seki C, et al. Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I. J Nucl Med. 2012;53(7):1065–73.PubMedCrossRef

30.

Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27(9):1533–9.PubMedCrossRef

31.

Kula NS, Baldessarini RJ, Tarazi FI, Fisser R, Wang S, Trometer J, et al. [3H]beta-CIT: a radioligand for dopamine transporters in rat brain tissue. Eur J Pharmacol. 1999;385(2–3):291–4.PubMedCrossRef

32.

Emond P, Garreau L, Chalon S, Boazi M, Caillet M, Bricard J, et al. Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4′-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(3′,4′-disubstituted phenyl)nortropane. New high-affinity and selective compound. J Med Chem. 1997;40(9):1366–72.PubMedCrossRef

33.

Jucaite A, Odano I, Olsson H, Pauli S, Halldin C, Farde L. Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study. Eur J Nucl Med Mol Imaging. 2006;33(6):657–68.PubMedCrossRef

34.

Odano I, Varrone A, Savic I, Ciumas C, Karlsson P, Jucaite A, et al. Quantitative PET analyses of regional [11C]PE2I binding to the dopamine transporter—application to juvenile myoclonic epilepsy. Neuroimage. 2012;59(4):3582–93.PubMedCrossRef

35.

Seki C, Ito H, Ichimiya T, Arakawa R, Ikoma Y, Shidahara M, et al. Quantitative analysis of dopamine transporters in human brain using [11C]PE2I and positron emission tomography: evaluation of reference tissue models. Ann Nucl Med. 2010;24(4):249–60.PubMedCrossRef

36.

Hirvonen J, Johansson J, Teräs M, Oikonen V, Lumme V, Virsu P, et al. Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test–retest reproducibility. J Cereb Blood Flow Metab. 2008;28(5):1059–69.PubMedCrossRef

37.

Shetty HU, Zoghbi SS, Liow J-S, Ichise M, Hong J, Musachio JL, et al. Identification and regional distribution in rat brain of radiometabolites of the dopamine transporter PET radioligand [11C]PE2I. Eur J Nucl Med Mol Imaging. 2007;34(5):667–78.PubMedCrossRef

38.

Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain. 1991;114(Pt 5):2283–301.PubMedCrossRef

39.

Gibb WR, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1991;54(5):388–96.PubMedCentralPubMedCrossRef

40.

Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. Pathophysiologic and clinical implications. N Engl J Med. 1988;318(14):876–80.PubMedCrossRef

41.

Cosgrove KP, Mazure CM, Staley JK. Evolving knowledge of sex differences in brain structure, function, and chemistry. Biol Psychiatry. 2007;62(8):847–55.PubMedCentralPubMedCrossRef

42.

Miller IN, Cronin-Golomb A. Gender differences in Parkinson’s disease: clinical characteristics and cognition. Mov Disord. 2010;25(16):2695–703.PubMedCentralPubMedCrossRef

43.

Hagemeier J, Dwyer MG, Bergsland N, Schweser F, Magnano CR, Heininen-Brown M, et al. Effect of age on MRI phase behavior in the subcortical deep gray matter of healthy individuals. AJNR Am J Neuroradiol. 2013;34:2144–51.PubMedCrossRef

Title: Age-related decline in dopamine transporter in human brain using PET with a new radioligand [18F]FE-PE2I
Authors: Yoshitoshi Shingai
Amane Tateno
Ryosuke Arakawa
Takeshi Sakayori
WooChan Kim
Hidenori Suzuki
Yoshiro Okubo
Publication date: 01-04-2014
Publisher: Springer Japan
Published in: Annals of Nuclear Medicine / Issue 3/2014
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-013-0798-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Age-related decline in dopamine transporter in human brain using PET with a new radioligand [¹⁸F]FE-PE2I

Abstract

Objective

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2014

Electrocardiographically gated 11C-hydroxyephedrine PET for the simultaneous assessment of cardiac sympathetic and contractile functions

Erratum to: 18F-FDG PET as a single imaging modality in pediatric neuroblastoma: comparison with abdomen CT and bone scintigraphy

Diagnostic value of 18F-FDG PET/CT in patients with TENIS syndrome: correlation with thyroglobulin levels

18F-FDG PET/CT is a valuable tool for relapsing polychondritis diagnose and therapeutic response monitoring

18F-fluorodeoxyglucose positron emission tomography for evaluation of thymic epithelial tumors: utility for World Health Organization classification and predicting recurrence-free survival

Studying the biological feasibility of [99mTc(CO)3]-dextran-cysteine-cysteine-mannose as a potential molecular radiopharmaceutical for sentinel node detection